Introducing SERB Pharmaceuticals

SERB Pharmaceuticals represents the combination of SERB, BTG Specialty Pharmaceuticals and Veriton Pharma to form a new, growing specialty pharmaceutical company focused on critical care and rare diseases.

We make treating complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families.

Who we are

SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research).

Today SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks.

As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.

Improving patients’ quality of life and offering hope is what motivates and inspires us.




Dedicated employees

Direct sales in






Latest news

  • 21 September 2023
    BTG Pharmaceuticals, a SERB company, to present data on ricin antidote development programme at the North American Congress of Clinical Toxicology
    SERB will present in vivo data for a polyclonal antibody in development as an antidote for ricin poisoning, on the first day of the upcoming NACCT in Montreal.
  • 13 July 2023
    SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat Therapeutics
    West Conshohocken, PA, 13 July 2023: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard® (uridine triacetate) and Xuriden® (uridine triacetate), from Wellstat Therapeutics. Both medicines are commercially available in the US and currently distributed across Europe on a named patient or compassionate use basis.  Jeremie Urbain, […]
  • 22 June 2023
    BTG Pharmaceuticals Statement on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Use of Glucarpidase (Voraxaze®) and
    West Conshohocken, PA, 22 June 2023:  BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute Lymphoblastic Leukemia, B-Cell Lymphomas, Pediatric Acute Lymphoblastic Leukemia, and Pediatric Aggressive Mature B-Cell Lymphomas. i-iv The updated guidelines: “The updated guidelines will help ensure that healthcare professionals understand the current […]

Latest insight

When Choosing Antivenom, Look at Cost Per Treatment—Not Cost Per Vial

Recent NASBR data suggests that the difference in total treatment cost between antivenom products is probably much less than healthcare providers think.

Read more
You are leaving the global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region